MET Inhibitor Strategy Bolsters Chemoimmunotherapy, Crushing Treatment Resistance in SCLC Patients

A recent multicenter study published in Cell Reports Medicine highlights a promising therapeutic strategy for small cell lung cancer (SCLC) that combines standard chemoimmunotherapy with a MET gene inhibitor. This approach, according to lead author Dr. Edurne Arriola, has shown strong preclinical and translational evidence for overcoming treatment resistance in a patient population with a notoriously poor prognosis.

SCLC represents about 15% of all lung cancer cases, and despite recent advances, the median overall survival with current treatment (anti-PD-L1 monoclonal antibodies with platinum and etoposide) is only about 12-13 months. A significant reason for this poor outcome is the activation of the hepatocyte growth factor (HGF) receptor (MET)/HGF signaling pathway, which induces chemoresistance through epithelial-mesenchymal transition (EMT) and creates an immunosuppressive tumor microenvironment.

The study’s investigators sought to determine if inhibiting the MET pathway could enhance the effectiveness of standard chemoimmunotherapy. Preclinical studies using SCLC mouse models demonstrated that adding savolitinib, a MET inhibitor, to existing therapies significantly improved antitumor effects and survival. This was attributed to a crucial modulation of the tumor microenvironment: the MET inhibitor reduced immunosuppressive myeloid-derived suppressor cells while increasing the infiltration of cytotoxic T cells, which are essential for an effective immune response. The findings suggest a dual-targeted approach that not only makes the tumor more vulnerable to chemotherapy but also empowers the immune system to fight the cancer more effectively.

Translational evidence from human SCLC samples further supported these findings. Researchers observed a higher prevalence of tumor-associated macrophages than tumor-infiltrating lymphocytes in patient samples, particularly in the SCLC-P subtype, which was associated with poorer responses to immunotherapy. Additionally, circulating HGF levels were found to correlate with tumor burden and potential treatment resistance. These observations underscore the importance of MET activation in SCLC resistance and point to these cellular and molecular markers as potential biomarkers and therapeutic targets.

The authors noted some limitations, including the heterogeneity of MET pathway activation in tumors and the use of mouse models with low MET expression in tumor cells. However, they stressed that the consistent results observed across their studies, along with the tolerable toxicity profile of the combined treatment in both preclinical and clinical settings, strongly support further evaluation of this strategy in clinical trials for SCLC patients. Dr. Arriola concluded that this decade-long research effort shows the strategy effectively slowed tumor growth and, in some cases, completely suppressed it, offering hope for a new approach to combat this aggressive disease.